122 related articles for article (PubMed ID: 38567478)
1. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract][Full Text] [Related]
2. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
3. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
Chevrier M; Bobbala D; Villalobos-Hernandez A; Khan MG; Ramanathan S; Saucier C; Ferbeyre G; Geha S; Ilangumaran S
BMC Cancer; 2017 Feb; 17(1):157. PubMed ID: 28235401
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p53 alterations in surgically treated prostate cancers.
Schlomm T; Iwers L; Kirstein P; Jessen B; Köllermann J; Minner S; Passow-Drolet A; Mirlacher M; Milde-Langosch K; Graefen M; Haese A; Steuber T; Simon R; Huland H; Sauter G; Erbersdobler A
Mod Pathol; 2008 Nov; 21(11):1371-8. PubMed ID: 18552821
[TBL] [Abstract][Full Text] [Related]
7. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
8. Differential CARM1 expression in prostate and colorectal cancers.
Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
[TBL] [Abstract][Full Text] [Related]
9. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
10. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer.
Shurbaji MS; Kalbfleisch JH; Thurmond TS
Hum Pathol; 1995 Jan; 26(1):106-9. PubMed ID: 7821906
[TBL] [Abstract][Full Text] [Related]
12. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
[TBL] [Abstract][Full Text] [Related]
14. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
15. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer.
Hasegawa Y; Matsubara A; Teishima J; Seki M; Mita K; Usui T; Oue N; Yasui W
Cancer Sci; 2007 Jan; 98(1):32-6. PubMed ID: 17052263
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 Protein in Prostate Carcinoma and its Correlation with Gleason Grade.
Wahid Z; Jaffer R; Khalid S; Khan HA; Riaz S
J Coll Physicians Surg Pak; 2020 Jun; 30(6):643-645. PubMed ID: 32703352
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
Incognito LS; Cazares LH; Schellhammer PF; Kuban DA; Van Dyk EO; Moriarty RP; Wright GL; Somers KD
Int J Oncol; 2000 Oct; 17(4):761-9. PubMed ID: 10995889
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
20. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
